I’m just refuting your idolatry, that management and experts are infallible How about you bullet point my claims, the company claims in a column next to it, and then we can discuss beyond empty generics?
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress